Vulsteke, C.
8  Ergebnisse:
Personensuche X
?
1

Prospective non-interventional BELOVA/BGOG-ov16 study on sa..:

Vergote, I ; Van Nieuwenhuysen, E ; De Waele, S...
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 32 (6) , p. 753 -760.  , 2023
 
?
2

Phase 3, randomized, open-label study of pembrolizumab plus..:

Marth, C ; Tarnawski, R ; Tyulyandina, A...
https://discovery.ucl.ac.uk/id/eprint/10143542/1/93.full.pdf.  , 2022
 
?
 
?
4

A20/TNFAIP3 heterozygosity predisposes to behavioral sympto..:

Daems, C ; Sékulic, M ; Vulsteke, V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474646/.  , 2019
 
?
5

Autoantibodies in idiopathic inflammatory myopathies:Clinic..:

Damoiseaux, Jan ; Vulsteke, Jean-Baptiste ; Tseng, Chih-Wei...
Damoiseaux , J , Vulsteke , J-B , Tseng , C-W , Platteel , A C M , Piette , Y , Shovman , O , Bonroy , C , Hamann , D , De Langhe , E , Musset , L , Chen , Y-H , Shoenfeld , Y , Allenbach , Y & Bossuyt , X 2019 , ' Autoantibodies in idiopathic inflammatory myopathies : Clinical associations and laboratory evaluation by mono- and multispecific immunoassays ' , Autoimmunity Reviews , vol. 18 , no. 3 , pp. 293-305 . https://doi.org/10.1016/j.autrev.2018.10.004.  , 2019
 
?
8

A20/TNFAIP3 heterozygosity predisposes to behavioral sympto..:

C. Daems ; M. Sékulic ; V. Vulsteke...
http://www.sciencedirect.com/science/article/pii/S2666354619300183.  , 2020
 
1-8